会員登録
ログイン
【4595】ミズホメディー
体外検査用医薬品。
売上高
営業利益
経常利益
当期利益
{{models[key].tabname}}
| 決算期 | 日付 | 予・実 | 売上高 (百万円) |
対前回 | 修正率 | 修正率 | 営業利益 (百万円) |
対前回 | 修正率 | 修正率 | 経常利益 (百万円) |
対前回 | 修正率 | 修正率 | 当期利益 (百万円) |
対前回 | 修正率 | 修正率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024.12 | 2024/11/08 | Q3予 | 10,430 | → | 0.0% | 0.0% | 4,162 | → | 0.0% | 0.0% | 4,169 | → | 0.0% | 0.0% | 3,016 | → | 0.0% | 0.0% |
| 2024.12 | 2024/08/09 | Q2予 | 10,430 | → | 0.0% | 0.0% | 4,162 | → | 0.0% | 0.0% | 4,169 | → | 0.0% | 0.0% | 3,016 | → | 0.0% | 0.0% |
| 2024.12 | 2024/05/10 | Q1予 | 10,430 | → | 0.0% | 0.0% | 4,162 | → | 0.0% | 0.0% | 4,169 | → | 0.0% | 0.0% | 3,016 | → | 0.0% | 0.0% |
| 2024.12 | 2024/02/09 | 当初予 | 10,430 | - | - | - | 4,162 | - | - | - | 4,169 | - | - | - | 3,016 | - | - | - |
| 2023.12 | 2024/02/09 | 実 | 10,989 | ↑ | +1.0% | +3.8% | 5,151 | ↑ | +1.3% | +28.4% | 5,292 | ↑ | +0.9% | +31.5% | 3,774 | ↑ | +0.7% | +30.0% |
| 2023.12 | 2023/11/10 | Q3予 | 10,877 | ↑ | +2.7% | +2.7% | 5,086 | ↑ | +26.8% | +26.8% | 5,243 | ↑ | +30.3% | +30.3% | 3,748 | ↑ | +29.2% | +29.2% |
| 2023.12 | 2023/08/10 | Q2予 | 10,589 | → | 0.0% | 0.0% | 4,011 | → | 0.0% | 0.0% | 4,023 | → | 0.0% | 0.0% | 2,902 | → | 0.0% | 0.0% |
| 2023.12 | 2023/02/10 | 当初予 | 10,589 | - | - | - | 4,011 | - | - | - | 4,023 | - | - | - | 2,902 | - | - | - |
| 2022.12 | 2023/02/10 | 実 | 17,581 | ↑ | +9.4% | +81.1% | 11,104 | ↑ | +13.1% | +145.7% | 11,070 | ↑ | +11.9% | +144.7% | 7,838 | ↑ | +12.9% | +143.0% |
| 2022.12 | 2022/11/11 | Q3予 | 16,076 | ↑ | +10.8% | +65.6% | 9,817 | ↑ | +15.1% | +117.2% | 9,895 | ↑ | +15.9% | +118.7% | 6,944 | ↑ | +15.7% | +115.3% |
| 2022.12 | 2022/08/10 | Q2予 | 14,503 | ↑ | +21.3% | +49.4% | 8,532 | ↑ | +31.3% | +88.8% | 8,538 | ↑ | +31.2% | +88.7% | 6,001 | ↑ | +30.5% | +86.1% |
| 2022.12 | 2022/05/09 | Q1予 | 11,959 | ↑ | +23.2% | +23.2% | 6,498 | ↑ | +43.8% | +43.8% | 6,506 | ↑ | +43.8% | +43.8% | 4,598 | ↑ | +42.6% | +42.6% |
| 2022.12 | 2022/02/10 | 当初予 | 9,709 | - | - | - | 4,520 | - | - | - | 4,524 | - | - | - | 3,225 | - | - | - |
| 2021.12 | 2022/02/10 | 実 | 13,137 | ↑ | +0.6% | +73.0% | 6,698 | ↑ | +5.3% | +225.5% | 6,700 | ↑ | +5.3% | +225.2% | 4,816 | ↑ | +5.0% | +219.2% |
| 2021.12 | 2021/11/08 | Q3予 | 13,062 | ↑ | +15.0% | +72.0% | 6,362 | ↑ | +34.0% | +209.1% | 6,364 | ↑ | +34.0% | +208.9% | 4,588 | ↑ | +31.6% | +204.0% |
| 2021.12 | 2021/08/10 | Q2予 | 11,358 | ↑ | +25.0% | +49.5% | 4,747 | ↑ | +53.8% | +130.7% | 4,751 | ↑ | +53.7% | +130.6% | 3,486 | ↑ | +51.4% | +131.0% |
| 2021.12 | 2021/05/10 | Q1予 | 9,083 | ↑ | +19.6% | +19.6% | 3,087 | ↑ | +50.0% | +50.0% | 3,092 | ↑ | +50.1% | +50.1% | 2,302 | ↑ | +52.6% | +52.6% |
| 2021.12 | 2021/02/10 | 当初予 | 7,595 | - | - | - | 2,058 | - | - | - | 2,060 | - | - | - | 1,509 | - | - | - |
| 2020.12 | 2021/02/10 | 実 | 4,205 | ↓ | -1.2% | -31.1% | 416 | ↑ | +77.0% | -49.8% | 415 | ↑ | +77.4% | -50.1% | 306 | ↑ | +85.5% | -50.6% |
| 2020.12 | 2020/11/09 | Q3予 | 4,254 | ↓ | -30.3% | -30.3% | 235 | ↓ | -71.7% | -71.7% | 234 | ↓ | -71.8% | -71.8% | 165 | ↓ | -73.4% | -73.4% |
| 2020.12 | 2020/05/11 | Q1予 | 6,100 | → | 0.0% | 0.0% | 829 | → | 0.0% | 0.0% | 831 | → | 0.0% | 0.0% | 620 | → | 0.0% | 0.0% |
| 2020.12 | 2020/03/19 | 当初予 | 6,100 | - | - | - | 829 | - | - | - | 831 | - | - | - | 620 | - | - | - |
| 2019.12 | 2020/02/12 | 実 | 6,427 | ↓ | -9.1% | -17.4% | 1,111 | ↓ | -15.9% | -21.9% | 1,111 | ↓ | -14.9% | -21.1% | 874 | ↓ | -9.4% | -15.6% |
| 2019.12 | 2019/11/08 | Q3予 | 7,072 | → | 0.0% | -9.1% | 1,321 | → | 0.0% | -7.1% | 1,306 | → | 0.0% | -7.2% | 965 | → | 0.0% | -6.8% |
| 2019.12 | 2019/08/10 | Q2予 | 7,072 | → | 0.0% | -9.1% | 1,321 | → | 0.0% | -7.1% | 1,306 | → | 0.0% | -7.2% | 965 | → | 0.0% | -6.8% |
| 2019.12 | 2019/05/13 | Q1予 | 7,072 | ↓ | -9.1% | -9.1% | 1,321 | ↓ | -7.1% | -7.1% | 1,306 | ↓ | -7.2% | -7.2% | 965 | ↓ | -6.8% | -6.8% |
| 2019.12 | 2019/02/12 | 当初予 | 7,779 | - | - | - | 1,422 | - | - | - | 1,408 | - | - | - | 1,035 | - | - | - |
| 2018.12 | 2019/02/12 | 実 | 6,423 | ↓ | -1.4% | +0.7% | 1,220 | ↑ | +9.6% | +33.6% | 1,211 | ↑ | +8.5% | +32.1% | 919 | ↑ | +7.7% | +30.0% |
| 2018.12 | 2018/11/09 | Q3予 | 6,517 | → | 0.0% | +2.2% | 1,113 | → | 0.0% | +21.9% | 1,116 | → | 0.0% | +21.7% | 853 | → | 0.0% | +20.7% |
| 2018.12 | 2018/08/10 | Q2予 | 6,517 | ↑ | +2.2% | +2.2% | 1,113 | ↑ | +21.9% | +21.9% | 1,116 | ↑ | +21.7% | +21.7% | 853 | ↑ | +20.7% | +20.7% |
| 2018.12 | 2018/05/11 | 修正予 | 6,376 | → | 0.0% | 0.0% | - | - | - | - | 917 | → | 0.0% | 0.0% | 707 | → | 0.0% | 0.0% |
| 2018.12 | 2018/02/13 | 当初予 | 6,376 | - | - | - | 913 | - | - | - | 917 | - | - | - | 707 | - | - | - |
| 2017.12 | 2018/02/13 | 実 | 5,624 | → | 0.0% | +3.8% | 850 | → | 0.0% | +29.4% | 851 | → | 0.0% | +29.7% | 660 | → | 0.0% | +31.2% |
| 2017.12 | 2018/01/29 | 修正予 | 5,624 | ↑ | +3.8% | +3.8% | 850 | ↑ | +29.4% | +29.4% | 851 | ↑ | +29.7% | +29.7% | 660 | ↑ | +31.2% | +31.2% |
| 2017.12 | 2017/11/13 | Q3予 | 5,417 | → | 0.0% | 0.0% | 657 | → | 0.0% | 0.0% | 656 | → | 0.0% | 0.0% | 503 | → | 0.0% | 0.0% |
| 2017.12 | 2017/08/10 | Q2予 | 5,417 | → | 0.0% | 0.0% | 657 | → | 0.0% | 0.0% | 656 | → | 0.0% | 0.0% | 503 | → | 0.0% | 0.0% |
| 2017.12 | 2017/05/12 | Q1予 | 5,417 | → | 0.0% | 0.0% | 657 | → | 0.0% | 0.0% | 656 | → | 0.0% | 0.0% | 503 | → | 0.0% | 0.0% |
| 2017.12 | 2017/02/10 | 当初予 | 5,417 | - | - | - | 657 | - | - | - | 656 | - | - | - | 503 | - | - | - |
| 2016.12 | 2017/02/10 | 実 | 4,961 | ↑ | +3.5% | +3.5% | 529 | ↑ | +7.7% | +7.7% | 524 | ↑ | +7.6% | +7.6% | 395 | ↑ | +12.2% | +12.2% |
| 2016.12 | 2016/08/10 | Q2予 | 4,795 | → | 0.0% | 0.0% | 491 | → | 0.0% | 0.0% | 487 | → | 0.0% | 0.0% | 352 | → | 0.0% | 0.0% |
| 2016.12 | 2016/05/12 | Q1予 | 4,795 | → | 0.0% | 0.0% | 491 | → | 0.0% | 0.0% | 487 | → | 0.0% | 0.0% | 352 | → | 0.0% | 0.0% |
| 2016.12 | 2016/02/12 | 当初予 | 4,795 | - | - | - | 491 | - | - | - | 487 | - | - | - | 352 | - | - | - |
| 2015.12 | 2016/02/12 | 実 | 4,082 | - | - | - | 388 | - | - | - | 371 | - | - | - | 257 | - | - | - |
